Hanmi Pharm Co Ltd., a prominent pharmaceutical company headquartered in Seoul, South Korea, has been a significant player in the healthcare sector since its inception in 1973. The company is listed on the Korea Exchange Stock Market and specializes in the development of treatments for a range of conditions, including diabetes, obesity, cancer, autoimmune diseases, and rare diseases. Hanmi Pharm’s commitment to innovation is evident in its extensive portfolio of clinical trials, which cover therapeutic areas such as neutropenia, anaemia, type II diabetes mellitus, hepatitis, and cancer. Additionally, the company is involved in the development of hyaluronate-based eye drops, hyalrheuma injection, and hyalu injection.
As of July 27, 2026, Hanmi Pharm’s stock closed at 374,500 KRW, reflecting a significant fluctuation over the past year, with a 52-week high of 647,000 KRW on February 23, 2026, and a 52-week low of 267,500 KRW on July 31, 2025. The company’s market capitalization stands at 4,748,740,132,864 KRW, underscoring its substantial presence in the pharmaceutical industry. Despite the volatility in its stock price, Hanmi Pharm maintains a price-to-earnings ratio of 32.09, indicating investor confidence in its growth potential and profitability.
Hanmi Pharm’s strategic focus on developing innovative treatments for complex diseases positions it as a leader in the pharmaceutical sector. The company’s dedication to advancing medical science through rigorous clinical trials and research initiatives highlights its role in addressing unmet medical needs. As it continues to expand its therapeutic offerings, Hanmi Pharm remains committed to improving patient outcomes and contributing to global healthcare advancements.
For more information about Hanmi Pharm Co Ltd. and its ongoing projects, stakeholders and interested parties are encouraged to visit the company’s official website at www.hanmipharm.com .
